Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cabaletta Bio, Inc. - Common Stock (NQ: CABA )

1.280 -0.060 (-4.48%)
Streaming Delayed Price Updated: 3:15 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 304,647
Open 1.340
Bid (Size) 1.280 (9)
Ask (Size) 1.290 (14)
Prev. Close 1.340
Today's Range 1.280 - 1.380
52wk Range 0.9857 - 14.02
Shares Outstanding 31,355,723
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform
From Cellares
Via Business Wire

Performance

YTD
-45.06%
-45.06%
1 Month
-25.58%
-25.58%
3 Month
-49.61%
-49.61%
6 Month
-68.24%
-68.24%
1 Year
-90.39%
-90.39%

More News

Read More
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
From Cabaletta Bio
Via GlobeNewswire
Looking Into Cabaletta Bio's Recent Short Interest
Via Benzinga
Peering Into Cabaletta Bio's Recent Short Interest
Via Benzinga
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025
From Cabaletta Bio
Via GlobeNewswire
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
US Stocks Likely To Open In The Green To End November On A High: Are Markets Set For A Santa Claus Rally In December? Analysts Decode
Via Benzinga
Caballeta Bio Shares Surge The Most In 23 Months In A Single Day As It Unveils Plan To Meet FDA By 2025 For Systemic Sclerosis Drug Trial
Via Benzinga
Exposures Product Safety
Cabaletta Bio to Participate in Upcoming Investor Conferences in December
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
From Cabaletta Bio
Via GlobeNewswire
CABA Stock Earnings: Cabaletta Bio Misses EPS for Q2 2024
Via InvestorPlace
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges
Via Benzinga
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
From Cabaletta Bio
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.